These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 19476397)

  • 1. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.
    Díaz-Borjón A
    Drugs Aging; 2009; 26(4):273-93. PubMed ID: 19476397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics in rheumatoid arthritis.
    Sen D; Paul JR; Ranganathan P
    Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Rheumatoid Arthritis Treatments for 'Old' Patients: Results of a Systematic Review.
    Caporali R; Fakhouri WKH; Nicolay C; Longley HJ; Losi S; Rogai V
    Adv Ther; 2020 Sep; 37(9):3676-3691. PubMed ID: 32705531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core management principles in rheumatoid arthritis to help guide managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S03-8. PubMed ID: 22073933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
    Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.
    Radovits BJ; Kievit W; Laan RF
    Drugs Aging; 2009; 26(8):647-64. PubMed ID: 19685931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology.
    Ho CTK; Mok CC; Cheung TT; Kwok KY; Yip RML;
    Clin Rheumatol; 2019 Dec; 38(12):3331-3350. PubMed ID: 31485846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rheumatoid arthritis.
    Gaffo A; Saag KG; Curtis JR
    Am J Health Syst Pharm; 2006 Dec; 63(24):2451-65. PubMed ID: 17158693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a place for initial treatment with biological DMARDs in the early phase of RA?
    Nam JL; Emery P
    Best Pract Res Clin Rheumatol; 2013 Aug; 27(4):537-54. PubMed ID: 24315053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.